TXG
10x Genomics, Inc. · Healthcare · Medical - Healthcare Information Services
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 114 | +7 | 98.90M | $3.78B | +16 | −8 |
| Q1 2026 | 109 | +3 | 94.02M | $1.99B | +12 | −10 |
| Q4 2025 | 107 | +3 | 97.86M | $1.59B | +4 | — |
| Q3 2025 | 19 | -2 | 71.88M | $839.83M | — | −3 |
| Q2 2025 | 19 | +1 | 64.66M | $748.72M | +2 | −1 |
| Q1 2025 | 15 | 0 | 30.56M | $266.82M | +1 | −1 |
| Q4 2024 | 15 | +1 | 24.83M | $356.61M | +3 | −2 |
| Q3 2024 | 13 | 0 | 22.71M | $512.82M | +1 | −1 |
| Q2 2024 | 13 | — | 21.07M | $409.76M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 9.31M | — | $181.15M | 1.6% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 2.87M | — | $55.90M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 2.87M | — | $55.90M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Baillie Gifford ✦ | 2.74M | — | $53.33M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Baillie Gifford ✦ | 2.74M | — | $53.33M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Baillie Gifford ✦ | 2.74M | — | $53.33M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Baillie Gifford ✦ | 2.74M | — | $53.33M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 1.77M | — | $34.49M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passive) | 1.77M | — | $34.49M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Millennium Management ✦ | 1.36M | — | $26.47M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Norges Bank ✦ (passive) | 991.05K | — | $19.28M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Capital World Investors ✦ | 793.30K | — | $15.43M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 334.39K | — | $6.50M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 315.18K | — | $6.13M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 315.18K | — | $6.13M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 315.18K | — | $6.13M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Renaissance Technologies ✦ | 210.20K | — | $4.09M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | PRIMECAP Management ✦ | 186.80K | — | $3.63M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Two Sigma Investments ✦ | 136.78K | — | $2.66M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Marshall Wace ✦ | 35.40K | — | $688,550 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 328 holders, 124.40M shares, $2.59B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 2.27K sh · $129,902
Director · 5.28K sh · $302,377
Director · 17.00K sh · $978,880
Director · 3.00K sh · $176,175
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology